Degrader Clinic : 2021 Protein Degradation Congress USA

As a relatively new and emerging field of drug discovery, targeted protein degradation research has been fairly experimental until now. Though with 2 compounds in the clinic now, and more due to enter in 2021, rules are starting to emerge. This 1-day clinic aims to establish a rationale for degrader drug development: What makes a good and drug-like degrader? How can we improve toxicity profiles and predict resistance? What is the best practice to employ in my programme? These are questions that will be deliberated at the Degrader Clinic 2021.

DISCUSSION : Safety and efficacy risks to de-risk degradation and degradation targets
DISCUSSION : Safety and efficacy risks to de-risk degradation and degradation targets	· How will resistance play a part in small molecule degraders? ·· Will degradation strategies lead to autoimmune responses when considering non-oncogenic targets? ·· How can we improve toxicity profiles?	Andrew Benowitz - GSK Ian Churcher - Amphista Therapeutics Andrew Zhang - AstraZeneca	View Session
PANEL DISCUSSION: Establishing a rationale: what rules are emerging for degrader design
PANEL DISCUSSION: Establishing a rationale: what rules are emerging for degrader design	·· What makes a good degrader target when considering alternative degradation strategies (molecular glues/LYTACs/AUTACs etc)? ·· How can oral bioavailability be achieved? ·· What human pharmacology and dose predictions make a drug-like degrader? ·· How can in vivo work be translated to disease relevant settings and in the clinic? ·· How to choose an appropriate and effective e3 ligase?	Rhamy Zeid - C4 Therapeutics Inc Adam Gilbert - Pfizer Danette Daniels - Promega	View Session

Time Zone: (UTC-05:00) Eastern Time (US & Canada) []

Degrader Clinic: Wednesday 3rd March